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The recent advances in myeloma treatment result in significantly better outcomes, defined as increased 
progression free survival (pFs) and overall survival (os). since there is a proven correlation between 
the extend of response and prolonged survival, there is an urgent need for highly sensitive assays 
for the detection of minimal residual disease (MRD). Next generation flow cytometry has become a 
valuable approach for sensitive evaluation of the depth of complete response (CR). Here, we report the 
diagnostic performance and validation results of a single-tube 9-color panel assay. The validation design 
included intra-assay analysis measuring accuracy, inter-assay analysis estimating method’s linearity 
and precision and inter-assay analysis evaluating repeatability. Furthermore, in inter-operator analysis 
assessed the comparability of the result analysis of different operators. Staining stability was evaluated 
in age-of-stain experiments. our validation results show that a reliable detection of residual myeloma 
cells is feasible to a detection level of 10−5 with a single-tube assay for a variety of materials (peripheral 
blood, bone marrow and stem cell apheresis). this study establishes highly sensitive, fully standardized 
approach for MRD detection in myeloma that is ready for implementation in routine diagnostic 
laboratories.
Plasma cell myeloma is a hematologic neoplasm characterized by the proliferation of malignant plasma clones. 
With targeted therapies available, a considerable number of patients can achieve complete response and have a 
significantly better outcome, defined as increased progression free survival and overall survival1,2. However, only 
3 to 10% of plasma cell myeloma patients who have received high dose therapy will remain in complete remission 
for more than ten years3, while the majority will eventually relapse and undergo further treatment. Since there is 
a correlation between the extend of response and prolonged survival, there is an urgent need for highly sensitive 
assays for the detection of minimal residual disease (MRD)4,5. MRD is a more sensitive measure of response than 
conventional criteria and was shown to have an enhanced predictive value in comparison to standard methods5. 
Thus, MRD detection is very important for deciding whether a patient will undergo relapse-appropriate 
treatment2,6.
Multiparameter flow cytometry enables robust and cost effective monitoring of minimal residual disease7 
in plasma cell myeloma patients. Because of the increased number of simultaneously used fluorochromes huge 
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variety of cells and subtypes with different characteristics can be assessed. This enables estimation of the MRD by 
detection and differentiation between normal and abnormal plasma cells.
In order for MRD assays to be highly specific and sensitive, a combination of immunophenotypic markers 
that are able to identify and discriminate between normal and abnormal plasma cells is required1,8–10. CD38 and 
CD138 were used as gating markers, while CD19, CD27, CD45, CD56, CD81, CD200 and CD117 allowed for the 
identification of the most frequent deviation from the normal plasma cell phenotype. In addition, the presence 
of CD45 allowed for further phenotypic characterization of plasma cells and their quantification relative to the 
leukocyte count.
In order to obtain a quantification limit (LOQ)11, defined as the lowest concentration at which the analyte can 
be quantified, in the magnitude of ≤10−5 (i.e. one abnormal plasma cell detected in a population of ≥100,000 
leucocytes) the sample has to be enriched to a total leucocyte count of 3–5 million in a small volume (e.g. 100 μl) 
following blood cell counting. The obtained cell suspension has to be stained according to a standard operating 
procedure (SOP)11,12.
In this study, we present a highly sensitive and standardized procedure for assessing minimal residual disease 
in patients with plasma cell myeloma in peripheral blood, bone marrow as well as in apheresis product. Our 
results show that our assay due to its highly discriminative combination of antibodies and effective gating strategy 
can be easily applied and validated in high throughput flow cytometry laboratories.
Materials and Methods
Qualification of instruments and good manufacturing practice (GMP) training. Qualification 
of all cytometers used in the study was preceded by risk analysis using the Ishikawa (fishbone diagram) and risk 
mitigation strategy performed according to failure modes and effects analysis (FMEA)13. Moreover, all cytometers 
underwent qualification based on written SOPs. All procedures were described in SOPs and the technical staff 
was adequately trained in using the SOP Guard Software.
Blood and apheresis specimen collection. The study was approved by the Ethics Committee of the 
Charité – Universitätsmedizin, Berlin, Germany. All experiments were performed in accordance with relevant 
guidelines and regulations. Healthy individuals and plasma cell myeloma patients undergoing stem cell apheresis 
at the Charité – Universitätsmedizin, Berlin, Germany were recruited for this study. Written informed consent 
was obtained from all participants. Blood was collected into vacutainers (BD, Heidelberg, Germany) containing 
EDTA for anticoagulation. Apheresis samples were collected with the Spectra Optia® Apheresis System (Terumo 
BCT) using the Continuous Mononuclear Cell Collection (CMNC) protocol.
Myeloma cell line. For the inter-assay analysis the myeloma cell line U266 was used. This cell line was estab-
lished from the peripheral blood of a 53-year-old male with IgE-secreting myeloma in 1968. U266 myeloma 
cells express the following markers: CD38weak+, cyCD79a+, CD138+, HLA-DR+, cylambda+, while they are 
negative for CD3−, CD5−, CD10−, CD13−, CD19−, CD20−, CD34−, CD37−, sm/cyIgG−, sm/cyIgM−, sm/
cykappa−, smlambda−.
Materials. Premixed, dry reagent cocktail (DuraClone RE PC antibody panel) as well as CD117 ECD (Clone: 
104D2D1) and CD3 ECD (Clone: UCHT1) antibodies used for the assessment of residual abnormal plasma 
cells and T cells were obtained from Beckman Coulter (Marseille, France). DuraClone RE PC tubes contained 
dried antibodies dosed to stain 3–5 × 106 leukocytes in 100–200 μl volume: CD81 FITC (Clone: JS64)14; CD27 
PE (Clone: 1A4CD27)15; CD19 PC5.5 (Clone: J3–119)16; CD200 PC7 (Clone: OX-104)17; CD138 APC (Clone: 



















5 × apheresis products 
3 × bone marrow 
Drop-in variants: 
CD3/CD117 ECD
normal whole blood 
spiked with U266 cells
1 × peripheral 
blood, 1 × bone 
marrow, 
1 × apheresis 
product




1 × bone marrow (0,4,6,8 h), 
1 × patient apheresis product 
(0, 4, 6, 8, 18 h), 1 × peripheral 
blood (0, 4, 6, 8, 24 h)
25 × normal 
whole blood
No. of samples with 
different plasma cell 
concentrations
6 (serial 
dilution) 8 (individual samples) 6 (serial dilution)




1 (for each type of material, 
4–5 different time points) 1
No. of replicates 3 1 3 in 5 different normal donors 10 1 10
1 in 25 different 
normal donors
Total no. of samples 18 8 90 30
25 (×5 different 
data analysis 
operators)
140 (including the 
repeatability samples) 25
Table 1. Overview of the validation process.
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sample staining procedure. Flow cytometric analysis was performed in the same single laboratory 
(Charité, Stem Cell Facility, Berlin, Germany) according to the manufacturer’s instructions (Beckman Coulter 
(Marseille, France) and according to the principles outlined by the European Myeloma Network21 (Tables 1, 2).
Briefly, the number of leucocytes in the specimens was determined using the hematology analyzer (Sysmex 
IP300 (XP-350), Sysmex). Leucocytes were then lysed using Versafix solution (VersaLyse, Beckman Coulter sup-
plemented with 0.25% IOTest Fixative Solution) at room temperature. Cell suspensions containing 3–5 × 106 
leukocytes were then centrifuged at 300 x g and resuspended in 100 μl phosphate buffered saline (PBS, Gibco). 
Cell suspensions were then transferred to DuraClone RE PC tubes and an appropriate volume of CD117 ECD 
antibody was added. After 15 min incubation at room temperature, cells were washed with PBS and centrifuged 
at 150 × g. The final pellet was resuspended in 500 μL PBS containing fixative solution (10% IOTest3 fixative 
solution, Beckman Coulter).
Data acquisition. Sample acquisition was performed on 10-color, 3-laser NAVIOS flow cytometers 
(Beckman Coulter) using predefined settings. Debris was excluded by appropriate adjustment of the FSC record-
ing trigger. Each sample was run twice in order to enhance the number of recorded events. Those duplicate read-
ings were merged using the Kaluza analysis software prior to the final analysis.
Acquisition settings were defined according to the manufacturer’s instructions using the eight DuraClone RE 
PC compensation tubes as well as single CD117 or CD3 staining. Obtained photomultiplier tube (PMT) voltages 
were used to define target channels for all scatter and fluorescence detectors using calibration bead particles 
(Flow-Set Pro beads, Beckman Coulter). Matching of target channels was verified daily with a new calibration run 
to prevent target mismatch. Furthermore, all instruments underwent daily verification of optical alignment and 
fluidics using other calibration bead particles (Flow Check beads, Beckman Coulter).
Data analysis. All acquired data files were analyzed using the Kaluza software, version 1.3 (Beckman 
Coulter). The two data files of the each stained sample were merged and analyzed. Cell doublets were excluded 
using either selection of events with highest FSC peak signals or with smallest width of FSC signal. Furthermore, 
cell debris was excluded from the analysis by using forward scatter time versus forward scatter dot plot. Dye 
aggregates were excluded from the analysis as outliers with high fluorescence intensities on the FITC detec-
tor and/or the near-infrared APC-AF750 detector. Absolute counts of the subpopulations were calculated in all 
panels by correlating CD45+ events with the white blood count obtained from all samples. Plasma cells were 
identified as events with high CD138 and high CD38 expression density. Abnormal phenotypes varied amongst 
patients and were identified by a combination of the following features: diminished expression of CD19, CD27, 
CD38, CD45, and/or CD81, overexpression of CD56, asynchronous expression of CD117 and CD200. Clusters 
of normal and abnormal plasma cells were identified using a 2D projection of all 9 fluorescent parameters (radar 
plot, Kaluza Analysis Software).
For the analysis of the inter-assay test, intra-assay test and inter-operator analysis, template analysis proto-
cols were created for each set of experiments. Data files of the same sample were analyzed by loading the data 
files of each time point (inter-assay test) or parallel staining (intra-assay test) into the appropriate template. 
Accordingly, for the inter-operator analysis data, files were analyzed by 5 different operators using the same tem-
plates. Furthermore, each analysis included verification of compensation and, if applicable, minor adjustments. 
In case of age of stain assays analysis (for the 8-, 18- and 24 h specimens) the sideward scatter (SSC) parameter 
was adjusted when necessary.
DURAClone RE PC MKSSC32 Euroflow
Assay format
No of tubes/no of colours/ 1/8/ 1/10/ 2/6/
Minimal cytometer 
configuration blue/4-red/2-violet/2 blue/4-red/3-violet/3 blue/4-red/2-violet/2
Formulation glassified layer in FACS tube, 1-test-unitized liquid single-color antibodies
3 different lyophilized bulk mixes for 
reconstitution
Compensation approach 8 colors, dry single-color antibodies, 1-test-unitized liquid single-color antibodies
4 color liquid single color antibodies 
(tandem dyes only), each tube with different 
compensation for dark red channel on red laser
Storage & shipping room temperature cold storage cold storage
Marker selection according to 
consensus21
CD200 added, CD117 missing 
(can be added as drop in) kappa, lambda added
kappa, lambda added CD27 and CD138 missing 
(can be added as drop in)
Mode of application
Sample type bone marrow*, peripheral blood, apheresis product bone marrow bone marrow*
Lysing method
bulk lysis of a volume 
equivalent to at least 5 × 106 
leukocytes
bulk lysis of a volume equivalent 
to 20 × 106 leukocytes
bulk lysis of a volume equivalent to at least 
20 × 106 leukocytes (2 × 10 × 106)
Staining capacity 5 × 106 leukocytes* all recovered cells from bulk lysis 10 × 10
6 leukocytes*
Staining mode surface surface and intracellular 1 × surface; 1 × surface and intracellular
Theoretical LOD/LOQ (20/50 
positive events; %CD45+) 
based on 1/2 staining capacity
8 × 106/2 × 105 2 × 10
6/5 × 106 (10 × 106 cells 
staining capacity) 4 × 10
6/1 × 105
Table 2. Comparison of different flow cytometry based MRD methods.
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Gated event counts were exported to Excel (Microsoft, Redmond, WA, USA) for the calculation of the fre-
quencies of the subpopulations together with the respective mean fluorescence intensities and related standard 
deviation. Coefficients of variation (CVs) were calculated for each subpopulation frequency from replicates pre-
pared from the same sample. The CVs obtained in intra- and inter-assay analysis were compared with the CVs as 
expected for the Poisson distribution characteristics.
Design of validation approach. Design of the validation of the residual plasma cells measurement was 
based on the current recommendation10,22,23. Specifically, the validation design included intra-assay analysis 
measuring accuracy, inter-assay analysis estimating method’s linearity and precision and inter-assay analysis 
evaluating repeatability (Table 1). Furthermore, in inter-operator analysis the comparability of the result analysis 
of different operators was assessed. Stability of the staining was evaluated in age-of-stain experiments. For the 
intra-assay test, blood samples from healthy individuals were spiked with different concentrations of stem cell 
apheresis product from patients with plasma cell myeloma. For the inter-assay analysis blood from five healthy 
donors was collected and spiked with U266 cells at five different concentrations: 0,5000%; 0,0500%; 0,0050%; 
0,0010%; 0,0005%; 0,0003%.
For the inter-assay analysis, whole blood, stem cell apheresis and bone marrow samples were taken from three 
patients with multiple myeloma. For the inter-operator analysis, a data set consisting of 25 files (22 unique files, 3 
file doublets) was analyzed independently by five independent, trained operators.
Results
Intra-assay analysis: Accuracy. The aim of the intra-assay analysis was to evaluate the accuracy of assess-
ment of minimal residual disease in patients with plasma cell myeloma. 18 samples from normal donors with 6 
different concentrations of spiked U266 cells were assayed, recording 1,799 × 103 ± 481 × 103 CD45+ events. 
Samples were created by spiking whole blood from a healthy donor with patient apheresis product of known 
plasma cell frequencies as assayed by flow cytometry analysis. Final target frequencies ranged from 0.008–
0.0005% of CD45+ anomalous plasma cells, representing 8 anomalous plasma cells in 1 × 105 CD45+ to 1 
anomalous plasma cell in 2 × 105 CD45+ cells, respectively. Table 3 shows the results of normal samples spiked 
with patient apheresis products. CVs were in the expected range (Poisson noise) for all tested samples. Recovery 
of spiked cells was found at an average of 85% when referring to samples above the theoretical lower limit of 
quantitation (LLOQ) from 0.008% to 0.004% and 75% for samples above the theoretical lower limit of detection 
(LLOD) from 0.008% down to 0.002%. The theoretical lower limit of detection was calculated as the percentage 
of minimum 20 positive events in the total number of leucocytes acquired. Furthermore, the theoretical limit of 
quantification was calculated as the percentage of minimum 50 positive events in the total number of leucocytes 
acquired11,24,25.
Verification of drop-in options: Accuracy. The aim of the drop-in verification was to compare the accu-
racy of the assessment of minimal residual disease in patients with plasma cell myeloma while using additional 
antibodies. Five apheresis products and three bone marrow samples were stained in Duraclone RE PC tube par-
allel without additional anitibody, with CD3 and CD117 ECD drop-in. The addition of drop-in antibody did not 
compromise the performance of Duraclone RE PC tube staining (see Fig. 1B). Final frequencies of malignant 
plasma cells between different stainings of the same sample ranged from 0% to 0.01% of CD45+ cells whereas 
normal plasma cell frequencies ranged from 0% to 0.07% of CD45+ cells.
Furthermore, CD3 drop-in antibody was used to extend the analysis of the immune compartment. The fre-
quencies of residual T, B, and NK cells analyzed in 5 leukapheresis products are shown in Table 4.
Inter-assay analysis: precision/Linearity. The aim of the first set of experiments of the inter-assay anal-
ysis was to evaluate the precision and linearity of assessment of minimal residual disease in patients with plasma 
cell myeloma. 90 samples with 6 different concentrations of U266 cells across 5 different whole blood samples 
from normal donors were assayed recording 1,157 × 103 ± 176 × 103 CD45+ events. Samples were created by 
spiking whole blood from a healthy donor with U266 cells to create samples with known frequencies of this cell 
line. Final target frequencies ranged from 0.5% to 0.0005% of CD45+ anomalous plasma cells, representing 1 








Number of CD45+ 
(x103, mean from 3 
replicates)
Number of recovered 











0.0080% 0.0086% 107% 2,674 228 7% 7% 0.00075% 0.00187%
0.0060% 0.0048% 80% 2,037 98 8% 10% 0.00098% 0.00245%
0.0040% 0.0027% 68% 1,708 47 6% 15% 0.00117% 0.00293%
0.0020%* 0.0013% 64% 1,513 19 24% 23% 0.00132% 0.00330%
0.0010%** 0.0007% 69% 1,453 10 44% 32% 0.00138% 0.00344%
0.0005%** 0.0003% 57% 1,408 4 25% 50% 0.00142% 0.00355%
Table 3. Results from validation runs on intra-assay variation/accuracy (*represents values below theoretical 
LLOQ; **represents spiked values below the theoretical LLOD).
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Figure 1. (A) Overview of the gating strategy for rare events plasma cells using the apheresis sample of a 
patient with plasma cell myeloma. Two compiled data files of lysed and stained samples were analyzed as 
follows: exclusion of non-single events, debris and dye aggregates. Furthermore, plasma cells were identified 
as events with high CD138 and high CD38 expression density. Clusters of normal and abnormal plasma cells 
were defined using a 2D projection of all 9 fluorescent parameters (radar plot). An abnormal phenotype was 
defined as plasma cells with diminished expression of CD19, CD27, CD38, CD45, and/or CD81; overexpression 
of CD56; and asynchronous expression of CD117 and CD200. (B) Comparison of staining without and with 
different drop-in antibodies (represents example of drop-in verification).
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as approximated through linear regression by a linear equation y = 0.963 ×−1 × 10−4 with a correlation coeffi-
cient of R2 = 0.948 (Fig. 2). Table 5 shows the results of normal samples spiked with U266 cells. CVs were higher 
than expected (Poisson noise) for samples with frequencies from 0.5% to 0.005%. Recovery of spiked U266 cells 
was found at an average of 95% when referring to samples above the theoretical lower limit of detection (LLOD) 
or quantitation (LLOQ) from 0.5% to 0.005%. LLOD and LLOQ were calculated as described above.
Inter-assay analysis: Repeatability. In this set of experiments, the aim was to evaluate the repeatability of 
the assessment. 30 samples from three different sources were assayed: peripheral blood, bone marrow and aphere-
sis product from three different plasma cell myeloma patients. 10 staining replicates from each sample (peripheral 
blood, bone marrow and apheresis product) were performed and acquired.
382,6 × 103 ± 4,7 × 103 CD45+ events were recorded from 10 replicates of peripheral blood samples. Final 
frequencies of malignant plasma cells ranged from 0.03% to 0.02% of CD45+, representing 2 anomalous 
plasma cells in 1 × 104 CD45+ at the CV of 13%. Similarly, 10 replicates of bone marrow samples recorded 
355,8 × 103 ± 12,3 × 103 CD45+ events. The estimated frequencies of malignant plasma cells ranged from 0.04% 
to 0.03% of CD45+ anomalous plasma cells. The %CV was 3. Finally, 10 replicates of autologous apheresis prod-
uct were analyzed showing 396,4 × 103 ± 3,3 × 103 events. The ranged of from 0.08% to 0.07% of CD45+ anom-
alous plasma cells. The %CV was 7.
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(% lymph)




0.13% 0.01% 169 2 23205 78.6% 1.25% 9.36%
0.03% 0.04% 680 53 130277 69.78% 0.34% 18.79%
0% 0.01% 6 45 556943 81.32% 0.07% 6.34%
0.04% 0% 1071 1 94378 85.87% 3.82% 8.75%
0.45% 0.02% 9892 76 317374 72.59% 1.21% 23%
Table 4. Results from five leukapheresis products showing frequencies of malignant and normal plasma cells as 














Expected concentration of U266 cells
Figure 2. Linearity assessment. Black outlined circles represent data points from 6 different concentrations 
of U266 cells, spiked into whole blood samples from 5 different normal donors and run in triplicate. Red bars 
represent the mean of measured values at each concentration. Linear regression delivered a slope of 0.96 and a 
correlation coefficient of R2 = 0.948.
Spiked 
%CD45
Recovered %CD45 (mean 
from 3 replicates in 5 
normal whole blood 
samples)
Relative recovery of 
target frequency
Number of CD45+ 
(×103, mean from 3 
replicates)
Number of recovered 










0.5000% 0.4815% 96% 1,174 5996 20% 1% 0.0017% 0.0043%
0.0500% 0.0459% 92% 1,153 523 17% 4% 0.0017% 0.0043%
0.0050% 0.0049% 98% 1,157 56 38% 13% 0.0017% 0.0043%
0.0010%** 0.0009% 94% 1,131 10 47% 31% 0.0018% 0.0044%
0.0005%** 0.0005% 109% 1,155 6 47% 40% 0.0017% 0.0043%
0.0003%** 0.0005% 195% 1,164 3 64% 56% 0.0017% 0.0043%
Table 5. Results from validation runs on inter-assay linearity/precision (**represents spiked values below the 
theoretical LLOD).
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Inter-operator analysis. To evaluate the inter-operator variability a comparison of results from five dif-
ferent data analyses conducted by five independent operators was performed. Trained operators analyzed 25 
datasets of apheresis and whole blood samples. The validation data set included 22 unique files and 3 file doublets. 
Analyses of data sets with average event counts above 50 plasma cell events (malignant or normal), showed high 
consistency, with CVs lower than 25% (Fig. 3). Outliers of inter-operator CVs were observed in samples with low 
frequencies ranging from 200% CV for 25 plasma cells total to 0% for 8 plasma cells total.
Age-of-stain analysis. Age of stain analysis was performed in order to evaluate the stability of the staining 
over time. 10 replicates from a single bone marrow sample of a myeloma patient were analyzed immediately after 
staining as well as 4, 6 and 8 h later. The variability for a change from the baseline assessed directly after performed 
staining ranged from 2 to 13% across different time points. Table 6 and Fig. 4 show the bone marrow age-of-stain 
analysis with comparable cell frequencies and CVs across all time points.
Although the reproducibility of the analysis was shown across all sample types (bone marrow, peripheral 
blood and apheresis (data not shown)) even after 24 h, we note that a moderate shift in granularity, as shown by 
altered SSC, was observed that required adaptation of the gating.
Background from blank. In order to determine the limit of blank (LOB) defined as the highest measure-
ment result that is likely to be observed for a blank sample, 25 samples from healthy donors were collected and 
stained according to standard protocols. The number of detected plasma cells with abnormal phenotype ranged 
between 0 and 2, while the mean number of CD45+ cells was 1472,5 × 103 and the mean normal plasma cell 
number recorded was 330. The analysis was performed with a standard protocol and LOB was calculated as the 
mean result and the standard deviation (SD), following the formula: meanblank +1.645(SDblank). The calculated 
LOB was 0,76.
Discussion
Flow cytometry is a reliable, easy and cost effective tool for the assessment of minimal residual disease in patients 
with plasma cell myeloma26. Novel drugs significantly improve patients’ outcomes by achieving longer remis-
sions that cannot be measured reliably with standard methods such as immunofixation and electrophoresis5. On 
the other hand, molecular tests like allele-specific oligonucleotide (ASO)-PCR27 or next generation sequencing 
(NGS) of immunoglobulin rearranged genes28,29 require pre-treatment evaluation, have relatively high cost per 
sample and are time consuming. Although flow cytometry MRD testing is being performed by many laborato-
ries, there are major differences in antibody panels, gating strategies and minimal event counts30. The effort of 
minimalizing the laborious workflow and cost while preserving the robustness and sensitivity, has been recently 
shown by the EuroFlow Consortium31 and MSKCC group32 (see Table 2).
The presented, standardized assay addresses the urgent need for easy, applicable, lean and sensitive flow 















Figure 3. Results from validation runs on inter-operator analysis. White outlined circles represent numbers of 
normal plasma cells; black circles represent abnormal plasma cells estimated by the analysis.
Age of stain
0 h 4 h 6 h 8 h
Mean SD Mean SD Mean SD Mean SD
CD45+ (×103) 355,8 12,9 396,0 9,5 411,4 8,6 419,8 7,9
Normal plasma cells 210 14 212 27 222 18 203 16
Abnormal plasma cells (×103) 12,1 0,4 12,2 0,5 12,3 0,5 12,2 0,4
Table 6. Validation run on age-of-stain comparing analysis of 10 replicates from a single bone marrow sample 
of a myeloma patient at four different time points (0; 4; 6; 8 h).
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setting. Furthermore, this validation evaluated the capability of using different starting material like mobilized 
peripheral blood and stem cell apheresis for MRD evaluation.
The tested flow cytometry panel was designed based on current recommendation and results of clinical trials1,2,10  
and took advantage of room temperature stable dried antibodies, preformatted for one test in a assay tube as well 
as automated instrument setup and compensation routine33. Furthermore, analysis using a predefined template, 
including dynamic gates and radar plots34, allowed for a high level of standardization independent of the person-
nel performing the analysis. This leads to a simplified and easy protocol that can be expanded by including further 
markers (e.g. ECD and APC-AF700 conjugated fluorochromes), as shown here with the addition of the CD117 or 
CD3 antibody. Additional antibodies used as drop-ins did not compromise the performance of the assay.
Reliable assessment of minimal residual disease can only be achieved upon stringent validation of the diag-
nostic assay. Here, we presented a validation study that follows the current recommendation summarized in the 
consensus guidelines12,21,23 with the aim to demonstrate the ability of this assay to detect, in a reproducible and 
reliable manner, the presence of minimal residual disease.
Validation performed in compliance with ISO15189: 2012 accreditation guidelines for clinical laboratories 
requires a verification of the accuracy. To validate the accuracy of an assay it is necessary to compare average 
values obtained with a conventional true value. This presents a technical challenge, since there are currently no 
fully characterized reference materials available. Furthermore, there are no external quality assessment programs, 
while other techniques for MRD assessment like (ASO)-PCR or NGS have different sensitivities and specificity, 
making it difficult to use them as a comparison method35. In order to overcome those difficulties and determine 
the lower level of detection (LLOD), we used whole blood from a healthy donor and spiked it with apheresis 
product from a patient with plasma cell myeloma with active disease as estimated by standard means. Due to the 
amount and nature of the original sample the percentage of malignant plasma cells in the samples varied between 
0.008% and 0.0005% for CD45+ anomalous plasma cells. CVs were in the expected range: 7–25% (Poisson noise) 
Figure 4. (A) Validation run on age-of-stain comparing analysis of 10 replicates from a single bone marrow 
sample of a myeloma patient at 0, 4, 6 and 8 h. Each column represents a different cell subtype (black/white 
pattern – CD45+ cells, white – cells with normal plasma cell phenotype, black– cells with malignant plasma cell 
phenotype) and corresponding CV at different time points of analysis after staining. (B) Validation run on age-
of-stain comparing analysis of 10 replicates from a single peripheral blood sample of a myeloma patient at 0, 4, 
6, 8 and 24 h. Each column represents a different cell subtype (black/white pattern – CD45+ cells, white – cells 
with normal plasma cell phenotype, black– cells with malignant plasma cell phenotype) and corresponding CV 
at different time points of analysis after staining.
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for all samples. Calculated LLOQ lied at 0.002% and LLOD was shown for 0.001%. In cases of rare populations 
where the LLOD is 0.01% or lower a CV < 30% is acceptable22.
Inter-assay experiments demonstrated linearity of the assay with a linear regression slope of 0.96 and a correla-
tion coefficient of R2 = 0.948. Precision of the assay was analyzed in the dilution experiment with samples created 
by spiking whole blood from a healthy donor with U266 cells to create samples with known frequencies of this 
cell line. The CVs were higher than expected (Poisson noise) for samples with frequencies from 0.5% to 0.005%; 
this might be attributed to the modified gating strategy needed for identification of the U266 cellular phenotype 
as compared to native malignant plasma cells. Analysis of the blank samples from healthy donors showed a low 
LOB of 0.76. Furthermore, repeatability showed high consistency of the results, regardless of the material used 
and the age-of-stain for no more than 24 h.
The development and introduction of a highly standardized analysis procedure as well as the introduction of 
radar plots significantly simplified the analysis procedure. The performed inter-operator analysis showed that 
inter-operator variability which is highly dependent on the subset abundance33 can be significantly reduced. 
According to our analysis, the consistency in data evaluation with average event counts above 50 plasma cell 
events (abnormal or normal) can be very high with CVs lower than 25%11.
Although this standardized test has been validated to detect at least 20 abnormal plasma cells and quantify 
the cell concentration above 50 plasma cells, the actual sensitivity will depend on the adherence to the protocol 
and the quality of the sample11,24,25. Since the age of the sample significantly influences the variability, especially in 
low-abundant cell populations36, our assay was performed immediately after sample collection. Age-of-stain anal-
ysis showed that immediately following staining, samples could be measured up to 24 h post staining. Variability 
remained comparable for 24 h.
Our validation results show that a reliable detection of residual myeloma cells was feasible to a detection level 
of 0.0010% (10−5) with a single-tube assay for a variety of materials (peripheral blood, bone marrow and stem 
cell apheresis).
Our MRD detection approach is applicable to more than 98% of plasma cell myeloma patient samples run 
in our laboratory. Furthermore, valid estimation of the presence of minimal residual disease was possible from 
peripheral blood and stem cell products. Due to the high sensitivity and robustness of the assay there was no need 
of assessment of pretreatment samples from the patients37.
In summary, the presented validation results demonstrate a highly standardized, well streamlined and lean 
workflow approach for the assessment of minimal residual disease in plasma cell myeloma patients. The presented 
validation of the test followed the FDA-NCI roundtable guidelines7 and international consensus recommenda-
tions for myeloma flow cytometry based MRD quality control12,23.
Expanding the sample material to include peripheral blood and apheresis product will help to collect 
long-term data of their predictive value as well as extend their usage. Furthermore, wider usage of this MRD 
assessment standardized approach will allow reliable comparison between laboratories setting new standards in 
routine evaluation patients’ response to treatment.
Data Availability
The datasets generated during and analysed during the current study are available from the corresponding author 
on reasonable request.
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